肥胖影响非酒精性脂肪性肝病纤维化生物标志物的性能
横断面队列研究比较多种纤维化评分在超重/肥胖非酒精性脂肪性肝病(NAFLD)患者中的表现,发现ADAPT和FIB-4对≥F3纤维化识别能力最佳且不受BMI影响,而NFS、BARD和FIBC3的特异性随BMI升高而下降,NFS经BMI调整切点后可优化性能。
要点
- 在肥胖NAFLD患者中,ADAPT和FIB-4对≥F3纤维化的AUROC≥0.85且不受BMI影响。
- NFS、BARD和FIBC3的特异性随BMI升高而下降,NFS可通过BMI调整切点纠正。
- FIB-4序贯联合ADAPT或FIBC3可提高诊断≥F3纤维化的特异性。
核心结论
- 在肥胖患者中,性能最佳的纤维化生物标志物是ADAPT和廉价的FIB-4,二者不受BMI影响。
- 广泛使用的NFS在肥胖个体中失去特异性,可能通过BMI调整切点予以纠正。
研究设计与样本
- 横断面队列研究,比较简单纤维化评分(FIB-4、NFS、APRI、BARD、HFS)和纳入新表位生物标志物PRO-C3(ADAPT、FIBC3)或细胞角蛋白18(MACK-3)的新评分。
- 研究纳入内分泌科(n=307)和肝病科(n=71)接受肝活检的超重/肥胖患者,中位BMI 40.3(IQR 36.0-44.7)kg/m2;另研究859例较不肥胖的活检证实NAFLD患者以推导NFS的BMI调整切点。
- 研究设置于三级转诊中心。
主要发现
- 识别≥F3纤维化AUROC≥0.85的评分包括ADAPT、FIB-4、FIBC3和HFS;纤维化性NASH的最佳预测指标为MACK-3和ADAPT。
- NFS、BARD和FIBC3的特异性随BMI升高而下降。
- 推导并验证了NFS在BMI<30.0、30.0-39.9和≥40.0 kg/m2组中排除/纳入≥F3纤维化的新切点,优化了所有BMI水平下的性能。
- FIB-4序贯联合ADAPT或FIBC3提高了诊断≥F3纤维化的特异性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Guidelines recommend blood-based fibrosis biomarkers to identify advanced nonalcoholic fatty liver disease (NAFLD), which is particularly prevalent in patients with obesity. OBJECTIVE: To study whether the degree of obesity affects the performance of liver fibrosis biomarkers in NAFLD. DESIGN: Cross-sectional cohort study comparing simple fibrosis scores [Fibrosis-4 Index (FIB-4); NAFLD Fibrosis Score (NFS); aspartate aminotransferase to platelet ratio index; BARD (body mass index, aspartate-to-alanine aminotransferase ratio, diabetes); Hepamet Fibrosis Score (HFS)] and newer scores incorporating neo-epitope biomarkers PRO-C3 (ADAPT, FIBC3) or cytokeratin 18 (MACK-3). SETTING: Tertiary referral center. PATIENTS: We recruited overweight/obese patients from endocrinology (n = 307) and hepatology (n = 71) clinics undergoing a liver biopsy [median body mass index (BMI) 40.3 (interquartile range 36.0-44.7) kg/m2]. Additionally, we studied 859 less obese patients with biopsy-proven NAFLD to derive BMI-adjusted cutoffs for NFS. MAIN OUTCOME MEASURES: Biomarker area under the receiver operating characteristic (AUROC), sensitivity, specificity, and predictive values to identify histological stage ≥F3 fibrosis or nonalcoholic steatohepatitis with ≥F2 fibrosis [fibrotic nonalcoholic steatohepatitis (NASH)]. RESULTS: The scores with an AUROC ≥0.85 to identify ≥F3 fibrosis were ADAPT, FIB-4, FIBC3, and HFS. For fibrotic NASH, the best predictors were MACK-3 and ADAPT. The specificities of NFS, BARD, and FIBC3 deteriorated as a function of BMI. We derived and validated new cutoffs for NFS to rule in/out ≥F3 fibrosis in groups with BMIs <30.0, 30.0 to 39.9, and ≥40.0 kg/m2. This optimized its performance at all levels of BMI. Sequentially combining FIB-4 with ADAPT or FIBC3 increased specificity to diagnose ≥F3 fibrosis. CONCLUSIONS: In obese patients, the best-performing fibrosis biomarkers are ADAPT and the inexpensive FIB-4, which are unaffected by BMI. The widely used NFS loses specificity in obese individuals, which may be corrected with BMI-adjusted cutoffs.
引用
- Qadri S, Ahlholm N, Lønsmann I, et al. Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease. J Clin Endocrinol Metab. 2022. PMID: 34971370. doi:10.1210/clinem/dgab933
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。